What's Going On With Monopar Therapeutics Shares Friday?
Portfolio Pulse from Dylan Berman
Monopar Therapeutics shares are trading lower after a volatile session following an agreement with Alexion, AstraZeneca Rare Disease for a worldwide license to ALXN-1840, a drug for Wilson disease. Despite successful Phase 3 trials, Alexion had previously terminated the program. Monopar will handle further development and commercialization, with financial terms including upfront payments and royalties.
October 25, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Monopar Therapeutics shares fell sharply after announcing a licensing agreement with Alexion for ALXN-1840, a drug for Wilson disease. Despite successful Phase 3 results, the program was previously terminated by Alexion. Monopar will now lead development and commercialization, impacting its financials with upfront payments and royalties.
The sharp decline in Monopar's stock price suggests investor concern over the financial and developmental responsibilities associated with the ALXN-1840 program. Despite the drug's Phase 3 success, the previous termination by Alexion raises questions about its viability, impacting investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100